GlassScriptPhysician profile
Denise E Hamilton
NPI 1043657323
$11,598.41
in general payments reported to CMS, 2019-2025
41 companies · $2,482 in 2025
The $2,482 reported for 2025 was more than what 95% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,489 · 2022: $1,779 · 2023: $2,220 · 2024: $3,627 · 2025: $2,482.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,278 · Education: $51.18.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,278.41 |
| Education | $51.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,515.40 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,060.36 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $934.21 | 2021-2025 | Xifaxan |
| Janssen Biotech, INC. | $812.43 | 2021-2025 | Tremfya, Stelara, Simponi |
| Genzyme Corporation | $591.99 | 2021-2025 | |
| Qol Medical, LLC | $563.74 | 2021-2025 | Sucraid, Sucraid |
| Gilead Sciences, INC. | $485.01 | 2021-2025 | |
| Ironwood Pharmaceuticals, INC | $414.82 | 2021-2024 | Linzess |
| Ardelyx, INC. | $357.00 | 2022-2025 | Ibsrela |
| Pfizer INC. | $313.32 | 2021-2025 | |
| Phathom Pharmaceuticals, INC. | $232.87 | 2024-2025 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $231.24 | 2024 | Zeposia |
| Ipsen Biopharmaceuticals, INC | $219.88 | 2024-2025 | Iqirvo |
| Alnylam Pharmaceuticals INC. | $202.50 | 2022-2025 | Givlaari |
| Enterra Medical, INC. | $188.89 | 2023-2025 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $184.47 | 2021-2023 | |
| Amgen INC. | $181.08 | 2021-2024 | Amjevita, Avsola |
| Novo Nordisk INC | $163.62 | 2023-2024 | Wegovy |
| Intercept Pharmaceuticals, INC. | $161.44 | 2022-2025 | Ocaliva |
| Merck Sharp & Dohme LLC | $149.68 | 2021-2024 | Dificid |
| Madrigal Pharmaceuticals | $138.76 | 2024-2025 | Rezdiffra, Resmetirom |
| Boston Scientific Corporation | $131.49 | 2024 | |
| Celltrion USA INC. | $125.72 | 2024-2025 | Zymfentra, Vegzelma |
| Vifor Pharma, INC. | $120.80 | 2024 | Veltassa |
| Verrica Pharmaceuticals INC. | $119.09 | 2024 | Ycanth |
| Ars Pharmaceuticals Operations, INC. | $114.76 | 2025 | Neffy |
| Janssen Pharmaceuticals, INC | $113.91 | 2021 | |
| Ferring Pharmaceuticals INC. | $110.73 | 2021-2024 | Rebyota |
| Astrazeneca Pharmaceuticals LP | $109.52 | 2024 | |
| Lilly USA, LLC | $82.01 | 2024-2025 | Omvoh, Zepbound |
| Celgene Corporation | $79.71 | 2022-2024 | Zeposia |
| Aimmune Therapeutics, INC. | $67.04 | 2024 | |
| Organon LLC | $58.15 | 2022-2025 | Hadlima, Renflexis |
| Redhill Biopharma INC. | $50.25 | 2021 | |
| Daiichi Sankyo INC. | $41.66 | 2021-2024 | Injectafer |
| Vivus LLC | $41.44 | 2021-2025 | Pancreaze, Qsymia |
| Braintree Laboratories, INC. | $39.29 | 2022-2024 | Suflave, Sutab |
| Regeneron Healthcare Solutions, INC. | $35.69 | 2022-2024 | Dupixent |
| Merit Medical Systems INC | $19.78 | 2023 | Endomaxx Stent and Delivery System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.50 | 2024 | Cyltezo |
| Intra-Sana Laboratories | $15.16 | 2023 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Denise Hamilton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.